Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMegan SmithANAndrew D. Nguyen

Discussion

Loading...

Member takes

Overview

Observational analysis improved immune reconstitution and reduced graft vs host disease in transplant recipients, suggesting a favorable safety profile.

Key Points

  • Patients showed a notable improvement in immune reconstitution after reduced-dose cyclophosphamide treatment and abatacept therapy.
  • The cumulative incidence of graft vs host disease was 38.9%, with nearly all cases being grade 1/2, indicating manageable side effects.
  • Transplantation protocols incorporated reduced dose cyclophosphamide alongside abatacept for enhanced graft versus host disease prophylaxis.
  • These findings may enable future studies to refine treatment approaches for high-risk hematological malignancies.

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d886https://doi.org/10.1182/blood-2025-4196
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation2025
  2. 2ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen2025
  3. 3Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  4. 4Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025
  5. 5Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025